MR-guided stereotactic radiotherapy of infra-diaphragmatic oligometastases: Evaluation of toxicity and dosimetric parameters.
MR-linac
Oligometastatic disease
Risk-adaption
SABR
SBRT
Stereotactic ablative radiotherapy
Stereotactic body radiotherapy
Toxicity
Journal
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192
Informations de publication
Date de publication:
13 Jan 2024
13 Jan 2024
Historique:
received:
21
04
2023
revised:
15
11
2023
accepted:
08
01
2024
medline:
16
1
2024
pubmed:
16
1
2024
entrez:
15
1
2024
Statut:
aheadofprint
Résumé
The SOFT trial is a prospective, multicenter, phase 2 trial investigating magnetic resonance (MR)-guided stereotactic ablative radiotherapy (SABR) for abdominal, soft tissue metastases in patients with oligometastatic disease (OMD) (clinicaltrials.gov ID NCT04407897). We present the primary endpoint analysis of 1-year treatment-related toxicity (TRAE). Patients with up to five oligometastases from non-hematological cancers were eligible for inclusion. A risk-adapted strategy prioritized fixed organs at risk (OAR) constraints over target coverage. Fractionation schemes were 45-67.5 Gy in 3-8 fractions. The primary endpoint was grade ≥ 4 TRAE within 12 months post-SABR. The association between the risk of gastrointestinal toxicity and clinical and dosimetric parameters was tested using a normal tissue complication probability model. We included 121 patients with 147 oligometastatic targets, mainly located in the liver (41%), lymph nodes (35%), or adrenal glands (14%). Nearly half of all targets (48%, n = 71) were within 10 mm of a radiosensitive OAR. No grade 4 or 5 TRAEs, 3.5 % grade 3 TRAEs, and 43.7% grade 2 TRAEs were reported within the first year of follow-up. We found a significant association between grade ≥ 2 GI toxicity and the parameters GI OAR D
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
The SOFT trial is a prospective, multicenter, phase 2 trial investigating magnetic resonance (MR)-guided stereotactic ablative radiotherapy (SABR) for abdominal, soft tissue metastases in patients with oligometastatic disease (OMD) (clinicaltrials.gov ID NCT04407897). We present the primary endpoint analysis of 1-year treatment-related toxicity (TRAE).
MATERIALS AND METHODS
METHODS
Patients with up to five oligometastases from non-hematological cancers were eligible for inclusion. A risk-adapted strategy prioritized fixed organs at risk (OAR) constraints over target coverage. Fractionation schemes were 45-67.5 Gy in 3-8 fractions. The primary endpoint was grade ≥ 4 TRAE within 12 months post-SABR. The association between the risk of gastrointestinal toxicity and clinical and dosimetric parameters was tested using a normal tissue complication probability model.
RESULTS
RESULTS
We included 121 patients with 147 oligometastatic targets, mainly located in the liver (41%), lymph nodes (35%), or adrenal glands (14%). Nearly half of all targets (48%, n = 71) were within 10 mm of a radiosensitive OAR. No grade 4 or 5 TRAEs, 3.5 % grade 3 TRAEs, and 43.7% grade 2 TRAEs were reported within the first year of follow-up. We found a significant association between grade ≥ 2 GI toxicity and the parameters GI OAR D
Identifiants
pubmed: 38224916
pii: S0167-8140(24)00011-2
doi: 10.1016/j.radonc.2024.110090
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT04407897']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
110090Informations de copyright
Copyright © 2024 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.